pubmed-article:7711287 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:7711287 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
pubmed-article:7711287 | lifeskim:mentions | umls-concept:C0037083 | lld:lifeskim |
pubmed-article:7711287 | lifeskim:mentions | umls-concept:C1414387 | lld:lifeskim |
pubmed-article:7711287 | pubmed:issue | 6 | lld:pubmed |
pubmed-article:7711287 | pubmed:dateCreated | 1995-5-12 | lld:pubmed |
pubmed-article:7711287 | pubmed:abstractText | A number of serine/threonine kinase receptors have recently been identified. Most of the members of this family are type I or type II receptors for proteins in the transforming growth factor-beta (TGF-beta) superfamily. The type I and type II receptors form heteromeric receptor complexes after binding of the ligands, and transduce intracellular signals. TGF-beta type I receptor needs type II receptor for ligand binding, and type II receptor needs type I receptor for signalling. The signal transducing molecules that interact with heteromeric serine/threonine kinase receptor complexes remain to be elucidated; cyclin-dependent kinases and the retinoblastoma protein appear to be downstream elements in the antiproliferative pathway of TGF-beta. | lld:pubmed |
pubmed-article:7711287 | pubmed:language | eng | lld:pubmed |
pubmed-article:7711287 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7711287 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:7711287 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7711287 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7711287 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:7711287 | pubmed:month | Dec | lld:pubmed |
pubmed-article:7711287 | pubmed:issn | 1043-4682 | lld:pubmed |
pubmed-article:7711287 | pubmed:author | pubmed-author:YamashitaHH | lld:pubmed |
pubmed-article:7711287 | pubmed:author | pubmed-author:HeldinC HCH | lld:pubmed |
pubmed-article:7711287 | pubmed:author | pubmed-author:MiyazonoKK | lld:pubmed |
pubmed-article:7711287 | pubmed:author | pubmed-author:ten DijkePP | lld:pubmed |
pubmed-article:7711287 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:7711287 | pubmed:volume | 5 | lld:pubmed |
pubmed-article:7711287 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:7711287 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:7711287 | pubmed:pagination | 389-98 | lld:pubmed |
pubmed-article:7711287 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:7711287 | pubmed:meshHeading | pubmed-meshheading:7711287-... | lld:pubmed |
pubmed-article:7711287 | pubmed:meshHeading | pubmed-meshheading:7711287-... | lld:pubmed |
pubmed-article:7711287 | pubmed:meshHeading | pubmed-meshheading:7711287-... | lld:pubmed |
pubmed-article:7711287 | pubmed:meshHeading | pubmed-meshheading:7711287-... | lld:pubmed |
pubmed-article:7711287 | pubmed:meshHeading | pubmed-meshheading:7711287-... | lld:pubmed |
pubmed-article:7711287 | pubmed:year | 1994 | lld:pubmed |
pubmed-article:7711287 | pubmed:articleTitle | Signal transduction via serine/threonine kinase receptors. | lld:pubmed |
pubmed-article:7711287 | pubmed:affiliation | Ludwig Institute for Cancer Research, Biomedical Center, Uppsala, Sweden. | lld:pubmed |
pubmed-article:7711287 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:7711287 | pubmed:publicationType | Review | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7711287 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7711287 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7711287 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7711287 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7711287 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7711287 | lld:pubmed |